No tracked super-investor fund reported a position in Grifols SA (GRFS) in 2026 Q2 13F filings. Latest close $8.47 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.
No tracked fund reported a position in this stock in the latest 13F quarter. Browse all funds.
No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.
No closely related stocks by co-holding for this stock. Browse all stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Oakmark Funds | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +21.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 164 of 8,857 filers |
| Long-only filers among them | 164 |
| Change vs 2026 Q1 | -20 net · 158 entered · 178 exited |
| Shares reported, all filers | 142,763,625 |
| Reported value, all filers | $1.0B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2024 | 7.2B EUR |
| Net income · FY2024 | 212.8M EUR |
| Total assets · FY2024 | 21.4B EUR |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026.
| Shares short · Oct 15, 2026 | 6,990,415 |
| Days to cover | 15.90 |
Shares short at recent settlements — Jul 31, 2026: 3.5M · Aug 14, 2026: 3.5M · Aug 31, 2026: 3.4M · Sep 15, 2026: 3.4M · Sep 30, 2026: 7.0M · Oct 15, 2026: 7.0M.
Source: FINRA Equity Short Interest (biweekly settlement data).
Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 14, 2026 | BRANDES INVESTMENT PARTNERS, LP | SC 13G/A | 27,220,179 | 24.3% | Mar 31, 2026 | SEC filing |
| Feb 17, 2026 | Permian Investment Partners, LP | SC 13G/A | 18,607,262 | 7.1% | Oct 8, 2024 | SEC filing |
| Feb 12, 2026 | BRANDES INVESTMENT PARTNERS, LP | SC 13G/A | 23,453,429 | 20.7% | Dec 31, 2025 | SEC filing |
| Nov 12, 2025 | BRANDES INVESTMENT PARTNERS, LP | SC 13G/A | 29,126,291.55 | 19.6% | Sep 30, 2025 | SEC filing |
| Apr 9, 2025 | BRANDES INVESTMENT PARTNERS, LP | SC 13G/A | 18,761,824 | 16.4% | Mar 31, 2025 | SEC filing |
| Feb 14, 2025 | Permian Investment Partners, LP | SC 13G | 16,567,321 | 6.3% | Oct 8, 2024 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).
Federal contracts: $80.1M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $60.1M |
| FY2022 | $15.5M |
| FY2023 | $747.4K |
| FY2024 | $1.0M |
| FY2025 | $1.3M |
| FY2026 | $1.4M |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| HHSD200201793271C | Department of Health and Human Services | $458.4K | Apr 1, 2017 |
| HHSD200201794415C | Department of Health and Human Services | $319.1K | Jul 1, 2017 |
| HHSD200201690098C | Department of Health and Human Services | $221.7K | Jul 1, 2016 |
| FA301623P0020 | Department of Defense | $180.0K | Nov 29, 2022 |
| 36C26223N0622 | Department of Veterans Affairs | $98.9K | Aug 31, 2023 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
No Form 8-K filings for this ticker in the index (Jan 2023 – present).
Stocks A–Z · Track Record: how the signals scored · Practice timing on GRFS
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.